Glycomimetics Inc (GLYC) 8.06 $GLYC
Nasdaq stocks posting largest percentage decreases
AP - Mon May 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
GlycoMimetics Reports First Quarter 2014 Results
Business Wire - Thu May 08, 8:02AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended March 31, 2014. As of March 31, 2014, GlycoMimetics had cash and cash equivalents of $57.0 million, which reflects the company's January 2014 initial public offering (IPO) in which it sold 8,050,000 shares of its common stock at $8.00 per share, including the underwriters' exercise in full of their option to purchase 1,050,000 additional shares of common stock. The aggregate net proceeds to GlycoMimetics from the IPO, after underwriting discounts and commissions and offering expenses, were $57.3 million.
Should GlycoMimetics (GLYC) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:41AM CDT
GlycoMimetics has seen estimates rise over the past month for the current fiscal year by about 100%, but that is not yet reflected in its price.
GlycoMimetics Appoints Seasoned Business Development Executive Armand Girard as New Vice President, Corporate Development
Business Wire - Wed Apr 23, 8:15AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it has expanded its management team with the addition of Armand Girard as Vice President, Corporate Development. Mr. Girard has extensive partnering experience having completed collaborations, licenses, acquisitions and spinouts by and between leading pharmaceutical and biotech companies. As the GlycoMimetics Vice President of Corporate Development, he is responsible for corporate strategy, for pursuing partnering and licensing opportunities in support of the GlycoMimetics pipeline, and for managing the company's corporate and institutional alliances. Prior to joining GlycoMimetics, he held the position of Vice President for Technical Assessment at Shire Pharmaceuticals, and has more than 20 years of business development, research and development and project management experience. Prior to serving as Vice President for Technical Assessment, Mr. Girard served as a Senior Director for Business Development at Shire. He has held various roles in the biotechnology industry over the past 20 years for companies such as Strakan Life Sciences, Pro-Virus, Inc. and Otsuka Pharmaceuticals. Mr. Girard holds an M.B.A. from St. Joseph's University Haub School of Business, and a B.A. from Lehigh University.
GlycoMimetics Announces Presentation of Data on Rivipansel (GMI-1070) in Combination with Current FDA-Approved Treatment for Sickle Cell Disease
Business Wire - Mon Apr 14, 8:02AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that data for its lead clinical drug candidate, rivipansel (GMI-1070), was highlighted via one oral presentation and one poster at the 8th Annual Sickle Cell Disease Research and Educational Symposium and 37th National Sickle Cell Disease Scientific Meeting, held April 11-14, 2014, at the InterContinental Miami.
How GlycoMimetics (GLYC) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:39AM CDT
GlycoMimetics has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
GlycoMimetics, Inc. [GLYC] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Thu Apr 10, 9:00AM CDT
What:
Biotech Leader Testifies at Congressional Hearing on Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies
Business Wire - Wed Apr 09, 11:00AM CDT
Today, the House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled "Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies." Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
GlycoMimetics Presents Data on Its E-Selectin Antagonist at American Association for Cancer Research Annual Meeting 2014
Business Wire - Wed Apr 09, 8:02AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that three posters of preclinical research study data for its E-Selectin antagonist (GMI-1271) were highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2014. GlycoMimetics is initially exploring the clinical use of the drug to treat acute myeloid leukemia (AML). The company plans to initiate a Phase 1 trial of GMI-1271 in healthy volunteers during the second quarter of 2014.
Why GlycoMimetics (GLYC) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:58AM CDT
GlycoMimetics has decent short-term momentum and is seeing solid activity on the earnings estimate revision front. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on GLYC’s earnings for the coming quarter and year.
GlycoMimetics Appoints Tim Pearson to Board of Directors and as Audit Committee Chair
Business Wire - Tue Apr 01, 8:01AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the addition of Timothy Pearson to its Board of Directors. Mr. Pearson most recently held the position of Chief Financial Officer, Executive Vice President and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. Mr. Pearson led the company's financial activities, including performance management, investor relations, SEC compliance, capital strategy and planning, until SXC Health Solutions (now Catamaran Corporation) acquired Catalyst in 2012. Mr. Pearson had previously served as Chief Financial Officer and Executive Vice President of MedImmune, the global biologics business for AstraZeneca PLC, where he had functional responsibility for finance, information technology, strategic planning and governance, and was a member of MedImmune's Executive Team.
3 Stocks in Breakout Territory With Big Volume
at The Street - Tue Apr 01, 5:00AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
GlycoMimetics Reports Fourth Quarter and Year-End 2013 Results
Business Wire - Mon Mar 31, 8:02AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the fourth quarter and year ended December 31, 2013.
The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs
GlycoMimetics Announces Sudden Passing of Board Director and Audit Committee Member William Gust
Business Wire - Fri Mar 14, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) reported today with great sorrow the sudden passing of William "Bill" Gust, who had served as a director of the company since 2006 and as a member of the audit committee of the Company's board of directors.
GlycoMimetics to Present at Barclays Global Healthcare Conference
Business Wire - Mon Mar 10, 3:00PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Rachel King, Chief Executive Officer, will present an overview of the company at the Barclays Capital 2014 Global Healthcare Conference on March 13, 2014, at 9:30 a.m. Eastern Time. The Conference will take place March 11 through March 13, 2014, at the Loews Miami Hotel in Miami, FL.
GlycoMimetics to Present GMI-1271 Research Findings at AACR Annual Meeting 2014
Business Wire - Wed Mar 05, 8:15AM CST
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today plans to present findings from research studies of its E-Selectin antagonist (GMI-1271) with three posters at the American Association for Cancer Research (AACR) Annual Meeting 2014. The posters will focus on the novel glycomimetic drug candidate's potential as a treatment beyond hematological cancers to solid tumors (i.e., for breast cancer metastasis) as well as for its use in improving chemotherapy treatment. The AACR Annual Meeting 2014 will be held April 5-9 at the San Diego Convention Center.
Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25
Marketwire - Fri Feb 28, 8:00AM CST
Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX"
, a publicly traded biopharmaceutical company headquartered in San Diego, CA; and maintains its twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "There has been considerable partnership and M&A activity for companies working on Sickle Cell Disease. On Sept. 19th, 2012, Selexys Pharmaceuticals, Corp. entered into an agreement with Novartis Pharmaceuticals, the agreement with Novartis could reach up to $665 million. In October 2011, Pfizer signed a licensing deal with U.S. firm GlycoMimetics which may be worth up to $340 million, including an upfront payment as well as development, regulatory, and commercial milestones, plus royalties." Mr. Silver, concludes, "GlycoMimetics (NASDAQ: GLYC), the first biotech IPO of 2014, currently trades at a market cap of around $225M whereas MSTX is around $85M. GlycoMimetics has only completed a Phase 2 trial whereas MSTX is actively enrolling patients in a Phase 3 trial."
Nasdaq stocks posting largest percentage decreases
AP - Mon May 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
GlycoMimetics Reports First Quarter 2014 Results
Business Wire - Thu May 08, 8:02AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended March 31, 2014. As of March 31, 2014, GlycoMimetics had cash and cash equivalents of $57.0 million, which reflects the company's January 2014 initial public offering (IPO) in which it sold 8,050,000 shares of its common stock at $8.00 per share, including the underwriters' exercise in full of their option to purchase 1,050,000 additional shares of common stock. The aggregate net proceeds to GlycoMimetics from the IPO, after underwriting discounts and commissions and offering expenses, were $57.3 million.
Should GlycoMimetics (GLYC) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:41AM CDT
GlycoMimetics has seen estimates rise over the past month for the current fiscal year by about 100%, but that is not yet reflected in its price.
GlycoMimetics Appoints Seasoned Business Development Executive Armand Girard as New Vice President, Corporate Development
Business Wire - Wed Apr 23, 8:15AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it has expanded its management team with the addition of Armand Girard as Vice President, Corporate Development. Mr. Girard has extensive partnering experience having completed collaborations, licenses, acquisitions and spinouts by and between leading pharmaceutical and biotech companies. As the GlycoMimetics Vice President of Corporate Development, he is responsible for corporate strategy, for pursuing partnering and licensing opportunities in support of the GlycoMimetics pipeline, and for managing the company's corporate and institutional alliances. Prior to joining GlycoMimetics, he held the position of Vice President for Technical Assessment at Shire Pharmaceuticals, and has more than 20 years of business development, research and development and project management experience. Prior to serving as Vice President for Technical Assessment, Mr. Girard served as a Senior Director for Business Development at Shire. He has held various roles in the biotechnology industry over the past 20 years for companies such as Strakan Life Sciences, Pro-Virus, Inc. and Otsuka Pharmaceuticals. Mr. Girard holds an M.B.A. from St. Joseph's University Haub School of Business, and a B.A. from Lehigh University.
GlycoMimetics Announces Presentation of Data on Rivipansel (GMI-1070) in Combination with Current FDA-Approved Treatment for Sickle Cell Disease
Business Wire - Mon Apr 14, 8:02AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that data for its lead clinical drug candidate, rivipansel (GMI-1070), was highlighted via one oral presentation and one poster at the 8th Annual Sickle Cell Disease Research and Educational Symposium and 37th National Sickle Cell Disease Scientific Meeting, held April 11-14, 2014, at the InterContinental Miami.
How GlycoMimetics (GLYC) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:39AM CDT
GlycoMimetics has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
GlycoMimetics, Inc. [GLYC] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Thu Apr 10, 9:00AM CDT
What:
Biotech Leader Testifies at Congressional Hearing on Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies
Business Wire - Wed Apr 09, 11:00AM CDT
Today, the House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled "Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies." Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
GlycoMimetics Presents Data on Its E-Selectin Antagonist at American Association for Cancer Research Annual Meeting 2014
Business Wire - Wed Apr 09, 8:02AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that three posters of preclinical research study data for its E-Selectin antagonist (GMI-1271) were highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2014. GlycoMimetics is initially exploring the clinical use of the drug to treat acute myeloid leukemia (AML). The company plans to initiate a Phase 1 trial of GMI-1271 in healthy volunteers during the second quarter of 2014.
Why GlycoMimetics (GLYC) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:58AM CDT
GlycoMimetics has decent short-term momentum and is seeing solid activity on the earnings estimate revision front. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on GLYC’s earnings for the coming quarter and year.
GlycoMimetics Appoints Tim Pearson to Board of Directors and as Audit Committee Chair
Business Wire - Tue Apr 01, 8:01AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the addition of Timothy Pearson to its Board of Directors. Mr. Pearson most recently held the position of Chief Financial Officer, Executive Vice President and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. Mr. Pearson led the company's financial activities, including performance management, investor relations, SEC compliance, capital strategy and planning, until SXC Health Solutions (now Catamaran Corporation) acquired Catalyst in 2012. Mr. Pearson had previously served as Chief Financial Officer and Executive Vice President of MedImmune, the global biologics business for AstraZeneca PLC, where he had functional responsibility for finance, information technology, strategic planning and governance, and was a member of MedImmune's Executive Team.
3 Stocks in Breakout Territory With Big Volume
at The Street - Tue Apr 01, 5:00AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
GlycoMimetics Reports Fourth Quarter and Year-End 2013 Results
Business Wire - Mon Mar 31, 8:02AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the fourth quarter and year ended December 31, 2013.
The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs
GlycoMimetics Announces Sudden Passing of Board Director and Audit Committee Member William Gust
Business Wire - Fri Mar 14, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) reported today with great sorrow the sudden passing of William "Bill" Gust, who had served as a director of the company since 2006 and as a member of the audit committee of the Company's board of directors.
GlycoMimetics to Present at Barclays Global Healthcare Conference
Business Wire - Mon Mar 10, 3:00PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Rachel King, Chief Executive Officer, will present an overview of the company at the Barclays Capital 2014 Global Healthcare Conference on March 13, 2014, at 9:30 a.m. Eastern Time. The Conference will take place March 11 through March 13, 2014, at the Loews Miami Hotel in Miami, FL.
GlycoMimetics to Present GMI-1271 Research Findings at AACR Annual Meeting 2014
Business Wire - Wed Mar 05, 8:15AM CST
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today plans to present findings from research studies of its E-Selectin antagonist (GMI-1271) with three posters at the American Association for Cancer Research (AACR) Annual Meeting 2014. The posters will focus on the novel glycomimetic drug candidate's potential as a treatment beyond hematological cancers to solid tumors (i.e., for breast cancer metastasis) as well as for its use in improving chemotherapy treatment. The AACR Annual Meeting 2014 will be held April 5-9 at the San Diego Convention Center.
Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25
Marketwire - Fri Feb 28, 8:00AM CST
Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX"
, a publicly traded biopharmaceutical company headquartered in San Diego, CA; and maintains its twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "There has been considerable partnership and M&A activity for companies working on Sickle Cell Disease. On Sept. 19th, 2012, Selexys Pharmaceuticals, Corp. entered into an agreement with Novartis Pharmaceuticals, the agreement with Novartis could reach up to $665 million. In October 2011, Pfizer signed a licensing deal with U.S. firm GlycoMimetics which may be worth up to $340 million, including an upfront payment as well as development, regulatory, and commercial milestones, plus royalties." Mr. Silver, concludes, "GlycoMimetics (NASDAQ: GLYC), the first biotech IPO of 2014, currently trades at a market cap of around $225M whereas MSTX is around $85M. GlycoMimetics has only completed a Phase 2 trial whereas MSTX is actively enrolling patients in a Phase 3 trial." 
